化学性质：                                                                                                             

产品描述：                                                                                                            

NMI 8739 is a dopamine D2 autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine.

NMI 8739 is a dopamine D2 autoreceptor agonist[1], which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine[2]. NMI 8739 reduces nitric oxide (NO) production in LPS-stimulated RAW264.7 Macrophages. NMI 8739 elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 Release in RAW264.7 macrophages after LPS-stimulation. Production of PGE2 is concentration-dependently suppressed with a reduction of 25.3% at 100 nM NMI 8739 and a 75% reduction for 1 μM NMI 8739. 2 μM NMI 8739 significantly inhibits IL-6 and CCL-20 release up to 49% and 37%, respectively[3].

[1]. Gill Higgins, New drugs signal rapid growth of anti-obesity drug market. RESEARCH & DEVELOPMENT. 2 Nov 11K16 No. 1061 [2]. Shashoua VE, et al. N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Sci. 1996;58(16):1347-57. [3]. Wang Y, et al. N-Docosahexaenoyl Dopamine, an Endocannabinoid-like Conjugate of Dopamine and the n-3 Fatty Acid Docosahexaenoic Acid, Attenuates Lipopolysaccharide-Induced Activation of Microglia and Macrophages via COX-2. ACS Chem Neurosci. 2017 Mar 15;8(3):548-557.

特别提醒：